1. Scott, D.L., F. Wolfe, and T.W.J. Huizinga, Rheumatoid arthritis. Lancet, 2010. 376: p. 1094-1108.
2. Modena, V., G. Bianchi, and D. Roccatello, Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target? Autoimmunity Reviews, 2013. 12: p. 835-838.
3. Connolly, D., et al., Impact of Fatigue in Rheumatic Diseases in the Work Environment: A Qualitative Study. Int J Environ Res Public Health, 2015. 12: p. 13807-13822.
4. Malm, K., et al., Quality of life in patients with established rheumatoid arthritis: A phenomenographic study. SAGE Open Med, 2017. 5: p. 1-8.
5. Hunter, T.M., et al., Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int, 2017. 37: p. 1551–1557.
6. Hense, S., et al., Prevalence of rheumatoid arthritis in Germany based on health insurance data : Regional differences and first results of the PROCLAIR study. Z Rheumatol, 2016. 75: p. 819-827.
7. McDougall, C., K. Hurd, and C. Barnabe, Systematic review of rheumatic disease epidemiology in the indigenous populations of Canada, the United States, Australia, and New Zealand. Semin Arthritis Rheum, 2017. 46: p. 675-686.
8. Davatchi, F., et al., Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. Int J Rheum Dis, 2016. 19: p. 1056-1062.
9. Uhlig, T., R.H. Moe, and T.K. Kvien, The Burden of Disease in Rheumatoid Arthritis. PharmacoEconomics, 2014. 32: p. 841–851.
10. Lundkvist, J., F. Kastäng, and G. Kobelt, The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ, 2008. 8: p. 49-60.
11. Birnbaum, H., et al., Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin, 2010. 26: p. 77-90.
12. Yazdany, J., et al., Coverage For High Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. Arthritis Rheumatol, 2015. 67: p. 1474–1480.
13. Huscher, D., et al., Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis, 2015. 74: p. 738-745.
14. O'Dell, J.R., Therapeutic strategies for rheumatoid arthritis. New England Journal of Medicine, 2004. 350: p. 2591-2602.
15. Criscione, L.G. and E.W.S. Clair, Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Current opinion in rheumatology, 2002. 14: p. 204-211.
16. Dogra, S. and G. Khullar, Tumor necrosis factor-α antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol, 2013. 79 Suppl 7: p. S35-46.
17. Schoels, M., et al., Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis, 2010. 69: p. 995-1003.
18. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care, 2018. 41: p. 917-928.
19. Liljas, B., How to calculate indirect costs in economic evaluations. Pharmacoeconomics, 1998. 13: p. 1-7.
20. Details of workers’ wages in 2019.
21. Drummond, M. and G. Stoddart, Economic analysis and clinical trials. Control Clin Trials, 1984. 5: p. 115-128.
22. PPP conversion factor, GDP (LCU per international $) - Iran, Islamic Rep. World Bank.
23. Iran Statistic Centre
24. Mojahedian, M.M., et al., Estimating the Cost of Illness of Prostate Cancer in Iran. Clin Ther, 2019. 41: p. 50-58.
25. Baker, K.F. and J.D. Isaacs, Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis, 2018. 77: p. 175-187.
26. Hsieh, P.-H., et al., Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis, 2020. 79: p. 771-777.
27. Mennini, F.S., et al., Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients. Clin Drug Investig, 2017. 37: p. 375-386.
28. GDP, PPP (current international $) - Iran, Islamic Rep. World Bank.
29. Current health expenditure (% of GDP) - Iran, Islamic Rep. World Bank.
30. Hu, H., et al., Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China. Int J Rheum Dis, 2018. 21: p. 1572-1580.
31. Malhan, S., et al., The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Clin Exp Rheumatol, 2012. 30: p. 202-207.
32. Ruof, J., et al., Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis, 2003. 62: p. 544-549.
33. Hamuryudan, V., et al., Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey. Clin Exp Rheumatol, 2016. 34: p. 1033-1037.
34. Michaud, K., et al., Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum, 2003. 48: p. 2750-2762.
35. Naqvi, A.A., et al., Estimation of direct cost of managing rheumatoid arthritis treatment to Pakistani patients using real-world follow-up data. Int J Rheum Dis, 2020. 23: p. 325-333.
36. Catay, E., et al., Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era. Clinicoecon Outcomes Res, 2012. 4: p. 219–225.
37. Xu, C., et al., Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study. Arthritis Care Res (Hoboken), 2014. 66: p. 523-531.
38. Osiri, M., A. Maetzel, and P. Tugwell, The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. J Rheumatol, 2007. 34: p. 57-63.
39. Zhu, T.Y., L.-S. Tam, and E.K. Li, Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. Rheumatology (Oxford), 2011. 50: p. 1293-1301.
40. Filipovic, I., et al., Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford), 2011. 50: p. 1083-1090.